Literature DB >> 23650335

Approach to the patient with hypogonadotropic hypogonadism.

Letícia Ferreira Gontijo Silveira1, Ana Claudia Latronico.   

Abstract

Hypogonadotropic hypogonadism (HH) or secondary hypogonadism is defined as a clinical syndrome that results from gonadal failure due to abnormal pituitary gonadotropin levels. HH may result from either absent or inadequate hypothalamic GnRH secretion or failure of pituitary gonadotropin secretion. Several congenital and acquired causes, including functional and organic forms, have been associated with this condition. One important aspect of the HH diagnosis is that it may reflect the presence of a tumor of the hypothalamic pituitary region or even a systemic disease. On the other hand, functional forms of HH, characterized by a transient defect in GnRH secretion, are relatively common in women, in response to significant weight loss, exercise, or stress leading to hypothalamic amenorrhea. HH is typically characterized by low circulating sexual steroids associated with low or inappropriately normal gonadotropin levels. The precise and early diagnosis of HH can prevent negative physical and psychological sequelae, preserve normal peak bone mass, and restore the fertility in affected patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23650335     DOI: 10.1210/jc.2012-3550

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  34 in total

1.  Idiopathic hypogonadotropic hypogonadism reversal after testosterone replacement in a 34-year-old male.

Authors:  Owais Rashid; Nanik Ram; Saad Farooq; Zareen Kiran
Journal:  BMJ Case Rep       Date:  2017-06-05

2.  Clinical pregnancy in a woman with idiopathic hypogonadotropic hypogonadism and low AMH: utility of ovarian reserve markers in IHH.

Authors:  Crystal Chan; Kimberly Liu
Journal:  J Assist Reprod Genet       Date:  2014-08-12       Impact factor: 3.412

Review 3.  Sex differences in the physiology of eating.

Authors:  Lori Asarian; Nori Geary
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-31       Impact factor: 3.619

Review 4.  Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing's syndrome, adrenal insufficiency, and congenital adrenal hyperplasia.

Authors:  Hershel Raff; Susmeeta T Sharma; Lynnette K Nieman
Journal:  Compr Physiol       Date:  2014-04       Impact factor: 9.090

Review 5.  Pubertal development and regulation.

Authors:  Ana Paula Abreu; Ursula B Kaiser
Journal:  Lancet Diabetes Endocrinol       Date:  2016-02-04       Impact factor: 32.069

Review 6.  Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism--pathogenesis, diagnosis and treatment.

Authors:  Ulrich Boehm; Pierre-Marc Bouloux; Mehul T Dattani; Nicolas de Roux; Catherine Dodé; Leo Dunkel; Andrew A Dwyer; Paolo Giacobini; Jean-Pierre Hardelin; Anders Juul; Mohamad Maghnie; Nelly Pitteloud; Vincent Prevot; Taneli Raivio; Manuel Tena-Sempere; Richard Quinton; Jacques Young
Journal:  Nat Rev Endocrinol       Date:  2015-07-21       Impact factor: 43.330

7.  Ablation of KNDy Neurons Results in Hypogonadotropic Hypogonadism and Amplifies the Steroid-Induced LH Surge in Female Rats.

Authors:  Melinda A Mittelman-Smith; Sally J Krajewski-Hall; Nathaniel T McMullen; Naomi E Rance
Journal:  Endocrinology       Date:  2016-03-03       Impact factor: 4.736

8.  Efficacy of follitropin-alpha versus human menopausal gonadotropin for male patients with congenital hypogonadotropic hypogonadism.

Authors:  Mazhar Ortaç; Muhammed Hıdır; Nusret Can Çilesiz; Ateş Kadıoğlu
Journal:  Turk J Urol       Date:  2019-11-29

Review 9.  Molecular insights into the aetiology of female reproductive ageing.

Authors:  John R B Perry; Anna Murray; Felix R Day; Ken K Ong
Journal:  Nat Rev Endocrinol       Date:  2015-10-13       Impact factor: 43.330

Review 10.  Pros and cons of GnRHa treatment for early puberty in girls.

Authors:  Ruben H Willemsen; Daniela Elleri; Rachel M Williams; Ken K Ong; David B Dunger
Journal:  Nat Rev Endocrinol       Date:  2014-04-08       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.